Goldman picks China healthcare stocks for a post-AI trade

HONG KONG — Goldman Sachs has identified select Chinese healthcare equities as targets for a post-artificial intelligence sector rotation, according to a report published on Sept. 13, 2026, by CNBC Finance. The bank's equity strategy points institutional investors toward domestic medical and pharmaceutical names as broader market earnings momentum shows shifts away from technology infrastructure plays.

Strategic Context

The positioning shift follows an acceleration in corporate earnings across mainland markets. Chinese equities tracked by Goldman Sachs posted earnings growth at their highest quarterly pace in five years, according to the CNBC Finance report. This fundamental expansion provides the valuation and cash flow baseline for portfolio managers reallocating capital out of crowded tech trades and into defensive or structurally growing domestic sectors such as healthcare.

Forward Outlook

Allocators and operators tracking Greater China equities should monitor upcoming institutional portfolio rebalancing filings and sector-specific fund flows. As earnings metrics reach multi-year highs across the bank's tracked universe, the durability of this margin expansion will dictate whether institutional capital remains committed to healthcare or rotates further across domestic consumption and industrial value chains.